Back to results

Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC

Primary Purpose

Non-Small Cell Lung Cancer

Status

Active

Phase

Phase 3

Locations

International

Study Type

Interventional

Intervention

MEDI4736

Placebo

About this trial

This is an interventional treatment trial for Non-Small Cell Lung Cancer

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

Histologically confirmed diagnosis of primary non-small cell carcinoma of the lung. according to WHO Classification of Tumours (WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart. WHO/IARC Classification of Tumours, 4th Edition, Volume 7). Patients with large-cell neuroendocrine carcinomas are not eligible.
Patients must be classified post-operatively as Stage IB (≥ 4cm in the longest diameter), II or IIIA on the basis of pathologic criteria. Note: Although T3N2M0 tumours have been reclassified to stage IIIB in the 8th edition of the IASLC staging system, these patients remain eligible (as stage IIIA under the 7th edition criteria).
- Complete surgical resection of the primary NSCLC is also mandatory. All gross disease must have been removed at the end of surgery. All surgical margins of resection must be negative for tumour. Resection may be accomplished by open or VATS techniques

Note: Patients with synchronous primary tumours will not be eligible due to the potential uncertainty regarding their appropriate PD-L1 status.

Prior Systemic Therapy:

Pre-operative (neo-adjuvant) platinum based or other chemotherapy is not permissible.
Patients may have received prior post-operative platinum based chemotherapy as per standard of care.
No prior anticancer therapy for treatment of NSCLC other than standard post-operative adjuvant chemotherapy is permissible.

Radiation:

• Patients with N2 disease only who receive adjuvant post-operative radiation therapy are eligible provided they meet the protocol specified timing criteria for surgery, adjuvant chemotherapy and randomization. Pre-operative radiation therapy is not permissible.

The patient must have an ECOG performance status of 0, 1.
Hematology: . Absolute neutrophil count ≥ 1.5 x 109/L or ≥ 1,500/µl Platelets ≥ 100 x 109/L or ≥ 100,000/µl
Biochemistry:

Total bilirubin* ≤ institutional upper limit of normal Alkaline phosphatase ≤ 2.5 x institutional upper limit of normal AST(SGOT) and ALT(SGPT) ≤ 2.5 x institutional upper limit of normal Creatinine Clearance ≥ 40 ml/min

* excluding Gilbert's syndrome

Creatinine clearance to be measured directly by 24 hour urine sampling or as calculated by Cockcroft Formula:

Females: GFR = 1.04 x (140-age) x weight in kg serum creatinine in μmol/L Males: GFR = 1.23 x (140-age) x weight in kg serum creatinine in μmol/L

Patient able and willing to complete the QoL, economics and other questionnaires. The baseline assessment must already have been completed within required timelines prior to randomization. Inability (illiteracy, loss of sight, or other equivalent reason) to complete the questionnaires will not make the patient ineligible for the study. However, ability but unwillingness to complete the questionnaires will make the patient ineligible
Patient consent must be appropriately obtained in accordance with applicable local and regulatory requirements. Each patient must sign a consent form prior to enrollment in the trial to document their willingness to participate
Patients must be accessible for treatment and follow-up. Investigators must assure themselves the patients randomized on this trial will be available for complete documentation of the treatment, adverse events, and follow-up
Protocol treatment is to begin within 2 working days of patient randomization

Exclusion Criteria:

Patients with a history of other malignancies, except:
- adequately treated non-melanoma skin cancer,
- curatively treated in-situ cancer, or
- other malignancies curatively treated with no evidence of disease for ≥ 5 years following the end of treatment and which, in the opinion of the treating physician, do not have a substantial risk of recurrence of the prior malignancy.
A combination of small cell and non-small cell lung cancer, pulmonary carcinoid tumour or large-cell neuroendocrine carcinoma (LCNEC).
History of autoimmune disease, including but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis. NOTE: patients with Grave's disease and/or psoriasis not requiring systemic therapy within the last two years from randomization and patients with hypothyroidism (e.g. following Hashimoto syndrome) stable on hormone replacement are not excluded.
History of primary immunodeficiency, history of allogenic organ transplant that requires therapeutic immunosuppression and the use of immunosuppressive agents within 28 days of randomization* or a prior history of severe (grade 3 or 4) immune mediated toxicity from other immune therapy.
Live attenuated vaccination administered within 30 days prior to randomization.
History of hypersensitivity to MEDI4736 or any excipient.
Patients who have experienced untreated and/or uncontrolled cardiovascular conditions and/or have symptomatic cardiac dysfunction (unstable angina, congestive heart failure, myocardial infarction within the previous year or cardiac ventricular arrhythmias requiring medication, history of 2nd or 3rd degree atrioventricular conduction defects). Patients with a significant cardiac history, even if controlled, must have a LVEF > 50% within 12 weeks prior to randomization.
Concurrent treatment with other investigational drugs or anti-cancer therapy.
Patients with active or uncontrolled infections or with serious illnesses or medical conditions which would not permit the patient to be managed according to the protocol. This includes but is not limited to:
- known clinical diagnosis of tuberculosis;
- known active hepatitis B infection (positive HBV surface antigen (HBsAg)). Patients with a past or resolved hepatitis B infection (defined as presence of hepatitis B core antibody (anti-HBc) and absence of HBSAg) are eligible;
- known active hepatitis C infection. Patients positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RA;
- known human immunodeficiency virus infection (positive HIV antibodies).
- known pneumonitis or pulmonary fibrosis with clinically significant impairment of pulmonary function
Pregnant or lactating women. Women of childbearing potential must have a urine pregnancy test proven negative within 14 days prior to randomization. Men and women of child-bearing potential must agree to use adequate contraception.

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

MEDI4736

Placebo

Arm Description

MEDI4736 by intravenous infusion. Treatment from Day 1 for a maximum of 12 months or study drug withdrawal if this occurs earlier.

PLACEBO by intravenous infusion. Treatment from Day 1 for a maximum of 12 months or study drug withdrawal if this occurs earlier

Outcomes

Primary Outcome Measures

Compare Disease free survival (DFS) for patients with NSCLC that is PD-L1 expression TC ≥ 25% and patients without common activating EGFR mutations or ALK gene rearrangements

Secondary Outcome Measures

Disease-free survival in the remaining 5 patient sub-populations defined by PD-L1 expression levels and EGFR/ALK status

(PD-L1 TC ≥ 1% and patients without common activating EGFR mutations or ALK gene rearrangements; all patients without common activating EGFR mutations or ALK gene rearrangements; all PD-L1 TC ≥ 25%; all PD-L1 TC ≥ 1%; all randomized patients)

Compare overall survival (OS) for patients in the six patient sub-populations defined by PD-L1 expression levels and EGFR/ALK status

Compare Lung cancer specific survival for patients in the six patient sub-populations defined by PD-L1 expression levels and EGFR/ALK status

Evaluate the nature, severity and frequency of adverse effects and tolerability of MEDI4736

All patients who receive at least one dose of MEDI4376/placebo will be included in the safety analysis. Descriptive summary tables will be presented on safety parameters by treatment arm. There will be safety monitoring by the CCTG Data Safety Monitoring Committee (DSMC) every 6 months

Evaluate the Quality of life in the six patient sub-populations defined by PD-L1 expression levels and EGFR/ALK status

The quality of life (QoL) of patients will be assessed using EORTC QLQ-C30 and the lung cancer module (QLQ-LC13) incorporated.

Determine survival benefits participants judge necessary to make adjuvant immunotherapy worthwhile

Determine the incremental cost effectiveness and cost utility ratios for MEDI4736

Evaluate the predictive/prognostic significance of PD-L1 expression

Evaluation of changes in plasma/serum cytokines and other blood and tissue based biomarkers after treatment with MEDI4736 and at disease event

Explore polymorphisms that may be associated with outcomes

Full Information

NCT ID

NCT02273375

First Posted

October 22, 2014

Last Updated

August 3, 2023

Sponsor

Canadian Cancer Trials Group

Collaborators

Intergroupe Francophone de Cancerologie Thoracique, Australasian Lung Cancer Trials Group, National Health and Medical Research Council, Australia, National Cancer Institute (NCI), Naples, Central and Eastern European Oncology Group, Dutch Society of Physicians for Pulmonology and Tuberculosis, Korean Cancer Study Group, Fundación GECP, West Japan Oncology Group (WJOG), Chinese Thoracic Oncology Group

1. Study Identification

Unique Protocol Identification Number

NCT02273375

Brief Title

Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC

Official Title

A Phase III Prospective Double Blind Placebo Controlled Randomized Study of Adjuvant MEDI4736 In Completely Resected Non-Small Cell Lung Cancer

Study Type

Interventional

2. Study Status

Record Verification Date

March 2023

Overall Recruitment Status

Active, not recruiting

Study Start Date

February 24, 2015 (Actual)

Primary Completion Date

April 30, 2025 (Anticipated)

Study Completion Date

January 31, 2026 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title

Sponsor

Name of the Sponsor

Canadian Cancer Trials Group

Collaborators

4. Oversight

Studies a U.S. FDA-regulated Drug Product

Yes

Studies a U.S. FDA-regulated Device Product

Data Monitoring Committee

Yes

5. Study Description

Brief Summary

The purpose of this study is to find out whether it is better to receive a new drug, MEDI4736, or better to receive no further treatment after surgery (and possibly chemotherapy) for lung cancer.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study

Non-Small Cell Lung Cancer

7. Study Design

Primary Purpose

Treatment

Study Phase

Phase 3

Interventional Study Model

Parallel Assignment

Masking

ParticipantCare ProviderInvestigator

Allocation

Randomized

Enrollment

1415 (Actual)

8. Arms, Groups, and Interventions

Arm Title

MEDI4736

Arm Type

Experimental

Arm Description

MEDI4736 by intravenous infusion. Treatment from Day 1 for a maximum of 12 months or study drug withdrawal if this occurs earlier.

Arm Title

Placebo

Arm Type

Placebo Comparator

Arm Description

PLACEBO by intravenous infusion. Treatment from Day 1 for a maximum of 12 months or study drug withdrawal if this occurs earlier

Intervention Type

Drug

Intervention Name(s)

MEDI4736

Intervention Type

Drug

Intervention Name(s)

Placebo

Primary Outcome Measure Information:

Title

Compare Disease free survival (DFS) for patients with NSCLC that is PD-L1 expression TC ≥ 25% and patients without common activating EGFR mutations or ALK gene rearrangements

Time Frame

6.7 years

Secondary Outcome Measure Information:

Title

Disease-free survival in the remaining 5 patient sub-populations defined by PD-L1 expression levels and EGFR/ALK status

Description

Time Frame

8 years

Title

Compare overall survival (OS) for patients in the six patient sub-populations defined by PD-L1 expression levels and EGFR/ALK status

Time Frame

8 years

Title

Compare Lung cancer specific survival for patients in the six patient sub-populations defined by PD-L1 expression levels and EGFR/ALK status

Time Frame

8 years

Title

Evaluate the nature, severity and frequency of adverse effects and tolerability of MEDI4736

Description

Time Frame

every 6 months

Title

Evaluate the Quality of life in the six patient sub-populations defined by PD-L1 expression levels and EGFR/ALK status

Description

The quality of life (QoL) of patients will be assessed using EORTC QLQ-C30 and the lung cancer module (QLQ-LC13) incorporated.

Time Frame

8 years

Title

Determine survival benefits participants judge necessary to make adjuvant immunotherapy worthwhile

Time Frame

8 years

Title

Determine the incremental cost effectiveness and cost utility ratios for MEDI4736

Time Frame

8 years

Title

Evaluate the predictive/prognostic significance of PD-L1 expression

Time Frame

8 years

Title

Evaluation of changes in plasma/serum cytokines and other blood and tissue based biomarkers after treatment with MEDI4736 and at disease event

Time Frame

8 years

Title

Explore polymorphisms that may be associated with outcomes

Time Frame

Baseline only

10. Eligibility

Sex

All

Minimum Age & Unit of Time

18 Years

Accepts Healthy Volunteers

Eligibility Criteria

Inclusion Criteria: Histologically confirmed diagnosis of primary non-small cell carcinoma of the lung. according to WHO Classification of Tumours (WHO Classification of Tumours of the Lung, Pleura, Thymus and Heart. WHO/IARC Classification of Tumours, 4th Edition, Volume 7). Patients with large-cell neuroendocrine carcinomas are not eligible. Patients must be classified post-operatively as Stage IB (≥ 4cm in the longest diameter), II or IIIA on the basis of pathologic criteria. Note: Although T3N2M0 tumours have been reclassified to stage IIIB in the 8th edition of the IASLC staging system, these patients remain eligible (as stage IIIA under the 7th edition criteria). Complete surgical resection of the primary NSCLC is also mandatory. All gross disease must have been removed at the end of surgery. All surgical margins of resection must be negative for tumour. Resection may be accomplished by open or VATS techniques Note: Patients with synchronous primary tumours will not be eligible due to the potential uncertainty regarding their appropriate PD-L1 status. Prior Systemic Therapy: Pre-operative (neo-adjuvant) platinum based or other chemotherapy is not permissible. Patients may have received prior post-operative platinum based chemotherapy as per standard of care. No prior anticancer therapy for treatment of NSCLC other than standard post-operative adjuvant chemotherapy is permissible. Radiation: • Patients with N2 disease only who receive adjuvant post-operative radiation therapy are eligible provided they meet the protocol specified timing criteria for surgery, adjuvant chemotherapy and randomization. Pre-operative radiation therapy is not permissible. The patient must have an ECOG performance status of 0, 1. Hematology: . Absolute neutrophil count ≥ 1.5 x 109/L or ≥ 1,500/µl Platelets ≥ 100 x 109/L or ≥ 100,000/µl Biochemistry: Total bilirubin* ≤ institutional upper limit of normal Alkaline phosphatase ≤ 2.5 x institutional upper limit of normal AST(SGOT) and ALT(SGPT) ≤ 2.5 x institutional upper limit of normal Creatinine Clearance ≥ 40 ml/min * excluding Gilbert's syndrome Creatinine clearance to be measured directly by 24 hour urine sampling or as calculated by Cockcroft Formula: Females: GFR = 1.04 x (140-age) x weight in kg serum creatinine in μmol/L Males: GFR = 1.23 x (140-age) x weight in kg serum creatinine in μmol/L Patient able and willing to complete the QoL, economics and other questionnaires. The baseline assessment must already have been completed within required timelines prior to randomization. Inability (illiteracy, loss of sight, or other equivalent reason) to complete the questionnaires will not make the patient ineligible for the study. However, ability but unwillingness to complete the questionnaires will make the patient ineligible Patient consent must be appropriately obtained in accordance with applicable local and regulatory requirements. Each patient must sign a consent form prior to enrollment in the trial to document their willingness to participate Patients must be accessible for treatment and follow-up. Investigators must assure themselves the patients randomized on this trial will be available for complete documentation of the treatment, adverse events, and follow-up Protocol treatment is to begin within 2 working days of patient randomization Exclusion Criteria: Patients with a history of other malignancies, except: adequately treated non-melanoma skin cancer, curatively treated in-situ cancer, or other malignancies curatively treated with no evidence of disease for ≥ 5 years following the end of treatment and which, in the opinion of the treating physician, do not have a substantial risk of recurrence of the prior malignancy. A combination of small cell and non-small cell lung cancer, pulmonary carcinoid tumour or large-cell neuroendocrine carcinoma (LCNEC). History of autoimmune disease, including but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or glomerulonephritis. NOTE: patients with Grave's disease and/or psoriasis not requiring systemic therapy within the last two years from randomization and patients with hypothyroidism (e.g. following Hashimoto syndrome) stable on hormone replacement are not excluded. History of primary immunodeficiency, history of allogenic organ transplant that requires therapeutic immunosuppression and the use of immunosuppressive agents within 28 days of randomization* or a prior history of severe (grade 3 or 4) immune mediated toxicity from other immune therapy. Live attenuated vaccination administered within 30 days prior to randomization. History of hypersensitivity to MEDI4736 or any excipient. Patients who have experienced untreated and/or uncontrolled cardiovascular conditions and/or have symptomatic cardiac dysfunction (unstable angina, congestive heart failure, myocardial infarction within the previous year or cardiac ventricular arrhythmias requiring medication, history of 2nd or 3rd degree atrioventricular conduction defects). Patients with a significant cardiac history, even if controlled, must have a LVEF > 50% within 12 weeks prior to randomization. Concurrent treatment with other investigational drugs or anti-cancer therapy. Patients with active or uncontrolled infections or with serious illnesses or medical conditions which would not permit the patient to be managed according to the protocol. This includes but is not limited to: known clinical diagnosis of tuberculosis; known active hepatitis B infection (positive HBV surface antigen (HBsAg)). Patients with a past or resolved hepatitis B infection (defined as presence of hepatitis B core antibody (anti-HBc) and absence of HBSAg) are eligible; known active hepatitis C infection. Patients positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA; known human immunodeficiency virus infection (positive HIV antibodies). known pneumonitis or pulmonary fibrosis with clinically significant impairment of pulmonary function Pregnant or lactating women. Women of childbearing potential must have a urine pregnancy test proven negative within 14 days prior to randomization. Men and women of child-bearing potential must agree to use adequate contraception.

Overall Study Officials:

First Name & Middle Initial & Last Name & Degree

Glenwood Goss

Organizational Affiliation

Ottawa Hospital Research Institute, Ontario, Canada

Official's Role

Study Chair

Facility Information:

Facility Name

Banner MD Anderson Cancer Center

City

Gilbert

State/Province

Arizona

ZIP/Postal Code

85234

Country

United States

Facility Name

USC Norris/Comprehensive Cancer Centre

City

Los Angeles

State/Province

California

ZIP/Postal Code

9003308

Country

United States

Facility Name

National Jewish Health

City

Denver

State/Province

Colorado

ZIP/Postal Code

80206

Country

United States

Facility Name

University of Florida

City

Gainesville

State/Province

Florida

ZIP/Postal Code

32610-0277

Country

United States

Facility Name

H. Lee Moffitt Cancer Center

City

Tampa

State/Province

Florida

ZIP/Postal Code

33612

Country

United States

Facility Name

Duke University Medical Center

City

Durham

State/Province

North Carolina

ZIP/Postal Code

27710

Country

United States

Facility Name

Hematology and Oncology Associates of NEPA

City

Dunmore

State/Province

Pennsylvania

ZIP/Postal Code

18512

Country

United States

Facility Name

Thomas Jefferson University

City

Philadelphia

State/Province

Pennsylvania

ZIP/Postal Code

19107

Country

United States

Facility Name

The Reading Hospital Medical Center

City

West Reading

State/Province

Pennsylvania

ZIP/Postal Code

19611

Country

United States

Facility Name

Campbelltown Hospital

City

Campbelltown

State/Province

New South Wales

ZIP/Postal Code

2560

Country

Australia

Facility Name

Chris O'Brien Lifehouse

City

Camperdown

State/Province

New South Wales

ZIP/Postal Code

2050

Country

Australia

Facility Name

Coffs Habour Health Campus - NCCI

City

Coffs Harbour

State/Province

New South Wales

ZIP/Postal Code

2450

Country

Australia

Facility Name

Gosford Hospital

City

Gosford

State/Province

New South Wales

ZIP/Postal Code

2250

Country

Australia

Facility Name

Nepean Hospital

City

Kingswood

State/Province

New South Wales

ZIP/Postal Code

2751

Country

Australia

Facility Name

St. George Hospital, Cancer Care Centre

City

Kogarah

State/Province

New South Wales

ZIP/Postal Code

2217

Country

Australia

Facility Name

Liverpool Cancer Therapy Centre, Liverpool Hospital

City

Liverpool

State/Province

New South Wales

ZIP/Postal Code

2170

Country

Australia

Facility Name

Northern Cancer Institute St Leonards

City

St Leonards

State/Province

New South Wales

ZIP/Postal Code

2065

Country

Australia

Facility Name

Westmead Hospital

City

Westmead

State/Province

New South Wales

ZIP/Postal Code

2145

Country

Australia

Facility Name

Sunshine Coast University Hospital

City

Birtinya

State/Province

Queensland

ZIP/Postal Code

4575

Country

Australia

Facility Name

Princess Alexandra Hospital

City

Brisbane

State/Province

Queensland

ZIP/Postal Code

4102

Country

Australia

Facility Name

The Prince Charles Hospital

City

Chermside

State/Province

Queensland

ZIP/Postal Code

4032

Country

Australia

Facility Name

Royal Adelaide Hospital

City

Adelaide

State/Province

South Australia

ZIP/Postal Code

5000

Country

Australia

Facility Name

Mater Medical Centre

City

Brisbane

State/Province

South, QLD

ZIP/Postal Code

4101

Country

Australia

Facility Name

Royal Hobart Hospital

City

Hobart

State/Province

Tasmania

ZIP/Postal Code

7000

Country

Australia

Facility Name

Monash Medical Centre

City

Clayton

State/Province

Victoria

ZIP/Postal Code

3168

Country

Australia

Facility Name

Frankston Hospital - Peninsula Oncology Centre

City

Frankston

State/Province

Victoria

ZIP/Postal Code

3199

Country

Australia

Facility Name

Austin Hospital

City

Heidelberg

State/Province

Victoria

ZIP/Postal Code

3084

Country

Australia

Facility Name

Royal Melbourne Hospital Research Foundation

City

Parkville

State/Province

Victoria

ZIP/Postal Code

3050

Country

Australia

Facility Name

Epworth HealthCare - Richmond

City

Richmond

State/Province

Victoria

ZIP/Postal Code

3121

Country

Australia

Facility Name

Border Medical Oncology

City

Wodonga

State/Province

Victoria

ZIP/Postal Code

3690

Country

Australia

Facility Name

Fiona Stanley Hospital

City

Murdoch

State/Province

Western Australia

ZIP/Postal Code

6150

Country

Australia

Facility Name

Sir Charles Gairdner Hospital

City

Perth

State/Province

Western Australia

ZIP/Postal Code

6009

Country

Australia

Facility Name

St John of God Subiaco

City

Subiaco

State/Province

Western Australia

ZIP/Postal Code

6008

Country

Australia

Facility Name

Flinders Medical Center

City

Adelaide

ZIP/Postal Code

5042

Country

Australia

Facility Name

Canberra Hospital

City

Garran

ZIP/Postal Code

ACT 2605

Country

Australia

Facility Name

St. Vincent's Hospital

City

Victoria Park

ZIP/Postal Code

3065

Country

Australia

Facility Name

Suporte Nutricional e Quimioterapia LTDA PRONUTRIR

City

Fortaleza

State/Province

Ceara

ZIP/Postal Code

60810180

Country

Brazil

Facility Name

Hospital Evangelico de Cachoeiro de Itapemirim

City

Cachoeiro de Itapemirim

State/Province

Espirito Santo

ZIP/Postal Code

29308020

Country

Brazil

Facility Name

Cetus Hospital Dia Oncologia

City

Belo Horizonte

State/Province

Minas Gerais

ZIP/Postal Code

30110-022

Country

Brazil

Facility Name

Liga Norte Riograndense Contra o Cancer

City

Natal

State/Province

Rio Grande Do Norte

ZIP/Postal Code

59075740

Country

Brazil

Facility Name

Instituto Tacchini de Pesquisa em Saude

City

Bento Goncalves

State/Province

Rio Grande Do Sul

ZIP/Postal Code

95700068

Country

Brazil

Facility Name

Centro de Oncologia e Radioterapia (COR) Mae de Deus

City

Porto Alegre

State/Province

Rio Grande Do Sul

ZIP/Postal Code

90110270

Country

Brazil

Facility Name

Clinica de Neoplasias Litoral

City

Itajai

State/Province

Santa Catarina

ZIP/Postal Code

88301220

Country

Brazil

Facility Name

Faculdade de Medicina do ABC

City

Sao Paulo

State/Province

Santo Andre

ZIP/Postal Code

09060870

Country

Brazil

Facility Name

Fundacao Faculdade Regional de Medicina

City

Sao Jose do Rio Preto

State/Province

Sao Paulo

ZIP/Postal Code

15090-000

Country

Brazil

Facility Name

Instituto Nacional de Cancer (INCA)

City

Rio de Janeiro

ZIP/Postal Code

20231050

Country

Brazil

Facility Name

MHAT Serdika - Medical Oncology Clinic

City

Sofia

ZIP/Postal Code

1003

Country

Bulgaria

Facility Name

MHAT Nadezhda Hospital

City

Sofia

ZIP/Postal Code

1330

Country

Bulgaria

Facility Name

Medical Centre Synexus

City

Sofia

ZIP/Postal Code

1784

Country

Bulgaria

Facility Name

Tom Baker Cancer Centre

City

Calgary

State/Province

Alberta

ZIP/Postal Code

T2N 4N2

Country

Canada

Facility Name

Cross Cancer Institute

City

Edmonton

State/Province

Alberta

ZIP/Postal Code

T6G 1Z2

Country

Canada

Facility Name

BCCA - Abbotsford Centre

City

Abbotsford

State/Province

British Columbia

ZIP/Postal Code

V2S 0C2

Country

Canada

Facility Name

BCCA - Fraser Valley Cancer Centre

City

Surrey

State/Province

British Columbia

ZIP/Postal Code

V3V 1Z2

Country

Canada

Facility Name

BCCA - Vancouver Cancer Centre

City

Vancouver

State/Province

British Columbia

ZIP/Postal Code

V5Z 4E6

Country

Canada

Facility Name

CancerCare Manitoba

City

Winnipeg

State/Province

Manitoba

ZIP/Postal Code

R3E 0V9

Country

Canada

Facility Name

The Moncton Hospital

City

Moncton

State/Province

New Brunswick

ZIP/Postal Code

E1C 6Z8

Country

Canada

Facility Name

Regional Health Authority B, Zone 2

City

Saint John

State/Province

New Brunswick

ZIP/Postal Code

E2L 4L2

Country

Canada

Facility Name

Dr. H. Bliss Murphy Cancer Centre

City

St. John's

State/Province

Newfoundland and Labrador

ZIP/Postal Code

A1B 3V6

Country

Canada

Facility Name

QEII Health Sciences Centre

City

Halifax

State/Province

Nova Scotia

ZIP/Postal Code

B3H 1V7

Country

Canada

Facility Name

Juravinski Cancer Centre at Hamilton Health Sciences

City

Hamilton

State/Province

Ontario

ZIP/Postal Code

L8V 5C2

Country

Canada

Facility Name

Kingston Health Sciences Centre

City

Kingston

State/Province

Ontario

ZIP/Postal Code

K7L 2V7

Country

Canada

Facility Name

London Regional Cancer Program

City

London

State/Province

Ontario

ZIP/Postal Code

N6A 5W9

Country

Canada

Facility Name

Stronach Regional Health Centre at Southlake

City

Newmarket

State/Province

Ontario

ZIP/Postal Code

L3Y 2P9

Country

Canada

Facility Name

Lakeridge Health Oshawa

City

Oshawa

State/Province

Ontario

ZIP/Postal Code

L1G 2B9

Country

Canada

Facility Name

Ottawa Hospital Research Institute

City

Ottawa

State/Province

Ontario

ZIP/Postal Code

K1H 8L6

Country

Canada

Facility Name

Algoma District Cancer Program

City

Sault Ste. Marie

State/Province

Ontario

ZIP/Postal Code

P6B 0A8

Country

Canada

Facility Name

Niagara Health System

City

St. Catharines

State/Province

Ontario

ZIP/Postal Code

L2S 0A9

Country

Canada

Facility Name

Health Sciences North

City

Sudbury

State/Province

Ontario

ZIP/Postal Code

P3E 5J1

Country

Canada

Facility Name

Thunder Bay Regional Health Sciences Centre/Thunder

City

Thunder Bay

State/Province

Ontario

ZIP/Postal Code

P7B 6V4

Country

Canada

Facility Name

Humber River Hospital

City

Toronto

State/Province

Ontario

ZIP/Postal Code

M3M 0B2

Country

Canada

Facility Name

Odette Cancer Centre

City

Toronto

State/Province

Ontario

ZIP/Postal Code

M4N 3M5

Country

Canada

Facility Name

Sinai Health System

City

Toronto

State/Province

Ontario

ZIP/Postal Code

M5G 1X5

Country

Canada

Facility Name

University Health Network

City

Toronto

State/Province

Ontario

ZIP/Postal Code

M5G 2M9

Country

Canada

Facility Name

PEI Cancer Treatment Centre

City

Charlottetown

State/Province

Prince Edward Island

ZIP/Postal Code

C1A 8T5

Country

Canada

City

Levis

State/Province

Quebec

ZIP/Postal Code

G6V 3Z1

Country

Canada

Facility Name

CHUM-Centre Hospitalier de l'Universite de Montreal

City

Montreal

State/Province

Quebec

ZIP/Postal Code

H2X 3E4

Country

Canada

Facility Name

The Jewish General Hospital

City

Montreal

State/Province

Quebec

ZIP/Postal Code

H3T 1E2

Country

Canada

Facility Name

The Research Institute of the McGill University

City

Montreal

State/Province

Quebec

ZIP/Postal Code

H4A 3J1

Country

Canada

Facility Name

Centre Integre Universitaire De Sante Et De Services

City

Montreal

State/Province

Quebec

ZIP/Postal Code

H4J 1C5

Country

Canada

Facility Name

University Institute of Cardiology and

City

Quebec City

State/Province

Quebec

ZIP/Postal Code

G1V 4G5

Country

Canada

Facility Name

Allan Blair Cancer Centre

City

Regina

State/Province

Saskatchewan

ZIP/Postal Code

S4T 7T1

Country

Canada

Facility Name

Saskatoon Cancer Centre

City

Saskatoon

State/Province

Saskatchewan

ZIP/Postal Code

S7N 4H4

Country

Canada

Facility Name

Beijing Cancer Hospital

City

Beijing

State/Province

Beijing

ZIP/Postal Code

100142

Country

China

Facility Name

Fujian Province Cancer Hospital

City

Fuzhou

State/Province

Fujian

ZIP/Postal Code

350014

Country

China

Facility Name

Guangdong General Hospital

City

Guangzhou

State/Province

Guangdong

ZIP/Postal Code

510080

Country

China

Facility Name

The Second Affiliated Hosp of Shantou Medical Colleg

City

Shantou

State/Province

Guangdong

ZIP/Postal Code

515041

Country

China

Facility Name

The People Hospital of Guangxi Zhuang Autonomous Reg

City

Nanning

State/Province

Guangxi

ZIP/Postal Code

530021

Country

China

Facility Name

Henan province Cancer Hospital

City

Zhengzhou

State/Province

Henan

ZIP/Postal Code

450008

Country

China

Facility Name

The Second Xiangya Hospital of Central South Univer

City

Changsha

State/Province

Hunan

ZIP/Postal Code

410011

Country

China

Facility Name

The First People Hospital of Yueyang

City

Yueyang

State/Province

Hunan

ZIP/Postal Code

414000

Country

China

Facility Name

Nanjing General Hospital

City

Nanjing

State/Province

Jiangsu

ZIP/Postal Code

210002

Country

China

Facility Name

The Affiliated Hospital Of Xuzhou Medical College

City

Xuzhou

State/Province

Jiangsu

ZIP/Postal Code

221000

Country

China

Facility Name

Xuzhou Central Hospital

City

Xuzhou

State/Province

Jiangsu

ZIP/Postal Code

221000

Country

China

Facility Name

Northern Jiangsu People Hospital

City

Yangzhou

State/Province

Jiangsu

ZIP/Postal Code

225000

Country

China

Facility Name

Shandong Cancer Hospital

City

Jinan

State/Province

Shandong

ZIP/Postal Code

250000

Country

China

Facility Name

The Affiliated Hospital Of Qingdao University

City

Qingdao

State/Province

Shandong

ZIP/Postal Code

266003

Country

China

Facility Name

Zhongshan Hospital Fudan University

City

Shanghai

State/Province

Shanghai

ZIP/Postal Code

200032

Country

China

Facility Name

Yunnan Provincial Cancer Hospital

City

Kunming

State/Province

Yunnan

ZIP/Postal Code

650118

Country

China

Facility Name

Sir run run shaw hospital School of Medicine

City

Hangzhou

State/Province

Zhejiang

ZIP/Postal Code

310016

Country

China

Facility Name

CRLCC - Paoli-Calmette

City

Marseille Cedex

State/Province

ZIP/Postal Code

156

Country

France

Facility Name

Hopital de la Croix-Rousse

City

Lyon

State/Province

Cedex 04

ZIP/Postal Code

69317

Country

France

Facility Name

Centre hospitalier universitaire de Montpellier

City

Montpellier

State/Province

Cedex 05

ZIP/Postal Code

34295

Country

France

Facility Name

AP-HP Hopital Tenon

City

Paris

State/Province

Cedex 20

ZIP/Postal Code

75970

Country

France

Facility Name

Hopital Albert Michallon

City

Grenoble

State/Province

Cedex 9

ZIP/Postal Code

38043

Country

France

Facility Name

CHRU de Tours - Hopital Bretonneau

City

Tours Cedex

State/Province

Tours Cedex 9

ZIP/Postal Code

37044

Country

France

Facility Name

CHU - Angers

City

Angers

ZIP/Postal Code

49033

Country

France

Facility Name

Centre Hospitalier - Avignon

City

Avignon

ZIP/Postal Code

84000

Country

France

Facility Name

Institut Sainte Catherine

City

Avignon

ZIP/Postal Code

84000

Country

France

Facility Name

Bayonne - Centre Hospitalier

City

Bayonne

ZIP/Postal Code

64100

Country

France

Facility Name

Hopital Jean Minjoz

City

Besancon Cedex

ZIP/Postal Code

25030

Country

France

Facility Name

Hopital Avicenne

City

Bobigny

ZIP/Postal Code

CEDEX 93009

Country

France

Facility Name

Polyclinique Bordeaux Nord

City

Bordeaux

ZIP/Postal Code

33077

Country

France

Facility Name

Boulogne - Ambroise Pare

City

Boulogne

ZIP/Postal Code

92104

Country

France

Facility Name

Caen - CHU

City

Caen

ZIP/Postal Code

14000

Country

France

Facility Name

Centre Hospitalier de Chambery

City

Chambery

ZIP/Postal Code

73000

Country

France

Facility Name

Centre Hospitalier de Cholet

City

Cholet

ZIP/Postal Code

49325

Country

France

Facility Name

HIA Percy

City

Clamart

ZIP/Postal Code

92141

Country

France

Facility Name

Clermont-Ferrand - CHU

City

Clermont-Ferrand

ZIP/Postal Code

63003

Country

France

Facility Name

Hopital Louis Pasteur

City

Colmar

ZIP/Postal Code

68024

Country

France

Facility Name

Annemasse - Centre Hospitalier Alpes Leman

City

Contamine Sur Arve

ZIP/Postal Code

74130

Country

France

Facility Name

Centre Hospitalier Sud Francilien

City

Corbeil-Essonnes

ZIP/Postal Code

91100

Country

France

Facility Name

Centre Hospitalier Intercommunal de Creteil

City

Creteil

ZIP/Postal Code

94000

Country

France

Facility Name

CHU Hopital du Bocage

City

Dijon

ZIP/Postal Code

21079

Country

France

Facility Name

Centre Hospitalier Intercommunal - Elbeuf

City

Elbeuf

ZIP/Postal Code

76503

Country

France

Facility Name

Centre Hospitalier departemental

City

La Roche Sur Yon

ZIP/Postal Code

85925

Country

France

Facility Name

Versailles - CH Andre Mignot

City

Le Chesnay

ZIP/Postal Code

78157

Country

France

Facility Name

Centre Hospitalier du Mans

City

Le Mans

ZIP/Postal Code

72037

Country

France

Facility Name

Lille - Hopital Calmette

City

Lille

ZIP/Postal Code

59037

Country

France

Facility Name

Centre Hospitalier Lyon Sud

City

Lyon

ZIP/Postal Code

69495

Country

France

Facility Name

Centre Hospitalier les Chanaux

City

Macon

ZIP/Postal Code

71018

Country

France

Facility Name

Hopital Europeen

City

Marseille

ZIP/Postal Code

13291

Country

France

Facility Name

Marseille - Hopital Nord

City

Marseille

ZIP/Postal Code

13915

Country

France

Facility Name

CH de la Region d'Annecy

City

Metz-Tessy

ZIP/Postal Code

74370

Country

France

Facility Name

Centre Hospitalier de Mulhouse

City

Mulhouse

ZIP/Postal Code

68070

Country

France

Facility Name

Centre Antoine Lacassagne - Nice

City

Nice

ZIP/Postal Code

06189

Country

France

Facility Name

Centre Hospitalier Regional Hopital de la Source

City

Orleans

ZIP/Postal Code

45000

Country

France

Facility Name

Paris - Institut Curie

City

Paris Cedex 5

ZIP/Postal Code

75248

Country

France

Facility Name

Hopital Saint Louis

City

Paris

ZIP/Postal Code

75010

Country

France

Facility Name

Fondation Hopital Saint Joseph

City

Paris

ZIP/Postal Code

75014

Country

France

Facility Name

Paris - HEGP

City

Paris

ZIP/Postal Code

75015

Country

France

Facility Name

Hopital Bichat

City

Paris

ZIP/Postal Code

75877

Country

France

Facility Name

Centre Hospitalier General de Pau

City

Pau

ZIP/Postal Code

64000

Country

France

Facility Name

Centre Hospitalier de Perigueux

City

Perigueux

ZIP/Postal Code

24019

Country

France

Facility Name

Centre Hospitalier Rene Dubos

City

Pontoise

ZIP/Postal Code

95301

Country

France

Facility Name

CHU de Rouen

City

Rouen

ZIP/Postal Code

76031

Country

France

Facility Name

Institut de Cancerologie de la Loire

City

Saint-priest-en-jarez

ZIP/Postal Code

42271

Country

France

Facility Name

Centre Hospitalier de Saint-Quentin

City

Saint-Quentin

ZIP/Postal Code

02100

Country

France

Facility Name

Nouvel Hopital Civil Hopitaux

City

Strasbourg

ZIP/Postal Code

67091

Country

France

Facility Name

Suresnes - Foch

City

Suresnes

ZIP/Postal Code

92151

Country

France

Facility Name

Thonon-les-Bains - Hopital Georges Pianta

City

Thonon Les Bains

ZIP/Postal Code

74203

Country

France

Facility Name

CHITS Toulon Sainte Musse

City

Toulon

ZIP/Postal Code

83056

Country

France

Facility Name

Hopital Larrey

City

Toulouse

ZIP/Postal Code

31059

Country

France

Facility Name

Villefranche sur Saone - CH

City

Villefranche Sur Saone

ZIP/Postal Code

69655

Country

France

Facility Name

Semmelweis University Pulmonology Department

City

Budapest

ZIP/Postal Code

1125

Country

Hungary

Facility Name

AOU Ospedali Riuniti Umberto I

City

Torrette

State/Province

ZIP/Postal Code

60126

Country

Italy

Facility Name

Azienda Ospedaliera San Giuseppe Moscati

City

Avellino

State/Province

ZIP/Postal Code

83100

Country

Italy

Facility Name

IRCCS Ospedale Oncologico Giovanni Paolo II

City

Bari

State/Province

ZIP/Postal Code

70124

Country

Italy

Facility Name

Instituto Clinico Humanitas

City

Rozzano (MI)

State/Province

Lombardia

ZIP/Postal Code

20089

Country

Italy

Facility Name

Ospedale S. Paolo - U.O. di Oncologia Medica

City

Milano

State/Province

ZIP/Postal Code

20142

Country

Italy

Facility Name

Azienda Ospedaliera di Perugia Santa Maria

City

Perugia

State/Province

ZIP/Postal Code

06129

Country

Italy

Facility Name

Centro di Riferimento Oncologico - CRO

City

Aviano

State/Province

ZIP/Postal Code

33081

Country

Italy

Facility Name

Fondazione Salvatore Maugeri Oncologia Medica

City

Pavia

State/Province

ZIP/Postal Code

27100

Country

Italy

Facility Name

OUC Oncologia Medica - Presidio Ospedaliero

City

Ravenna

State/Province

ZIP/Postal Code

48121

Country

Italy

Facility Name

Oncologia Medica IRCCS Arcispedale Maria

City

Reggio Emilia

State/Province

ZIP/Postal Code

42123

Country

Italy

Facility Name

Istituti Fisioterapici Ospitalieri IFO Istituto

City

Rome

State/Province

ZIP/Postal Code

00144

Country

Italy

Facility Name

A.O. Busto Arsizio - P.O. Saronno

City

Saronno

State/Province

ZIP/Postal Code

21047

Country

Italy

Facility Name

AOU Integrata Verona Policlinico GB

City

Verona

State/Province

ZIP/Postal Code

37134

Country

Italy

Facility Name

U.O. di Oncologia Medica Azienda Ospedaliera G Rummo

City

Benevento

ZIP/Postal Code

82100

Country

Italy

Facility Name

PO A Perrino ASL Brindisi - UOC Oncologia Medica

City

Brindisi

ZIP/Postal Code

72100

Country

Italy

Facility Name

AOU Policlinico Vittorio Emanuele UOC di Oncologia

City

Catania

ZIP/Postal Code

95125

Country

Italy

Facility Name

U.O. di Oncologia Ospedale Villa Scassi

City

Genova

ZIP/Postal Code

16149

Country

Italy

Facility Name

Intstituto Scientifico Romangnolo

City

Meldola

ZIP/Postal Code

47014

Country

Italy

Facility Name

European Institute of Oncology

City

Milan

ZIP/Postal Code

20141

Country

Italy

Facility Name

U.O.C. di Oncologia U.L.S.S. 13

City

Mirano

ZIP/Postal Code

30035

Country

Italy

Facility Name

Azienda Ospedaliera di Rilievo Nazionale

City

Napoli

ZIP/Postal Code

80131

Country

Italy

Facility Name

Dott. Fortunato Ciardiello,Cattedra Oncologia Medica

City

Napoli

ZIP/Postal Code

80131

Country

Italy

Facility Name

Unita Sperimentazioni Cliniche Istituto per lo

City

Napoli

ZIP/Postal Code

80131

Country

Italy

Facility Name

Universita Federico II UOC Oncologia Medica

City

Napoli

ZIP/Postal Code

80131

Country

Italy

Facility Name

UOC Oncologia Medica II Instituto Oncologio Veneto

City

Padova

ZIP/Postal Code

35128

Country

Italy

Facility Name

Azienda USL di Piacenza, Ospedale Gugliemimo Salieto

City

Piacenza

ZIP/Postal Code

29100

Country

Italy

Facility Name

Azienda Ospedaliera S. Camillo-Forlanin

City

Rome

ZIP/Postal Code

00152

Country

Italy

Facility Name

Japanese Red Cross Nagoya Daiichi Hospital

City

Nagoya

State/Province

Aichi

ZIP/Postal Code

453-8511

Country

Japan

Facility Name

Nagoya University Hospital

City

Nagoya

State/Province

Aichi

ZIP/Postal Code

466-8560

Country

Japan

Facility Name

National Cancer Center Hospital East

City

Kashiwa

State/Province

Chiba

ZIP/Postal Code

277-8577

Country

Japan

Facility Name

National Hospital Organization Shikoku Cancer Center

City

Matsuyama-shi

State/Province

Ehime

ZIP/Postal Code

791-0280

Country

Japan

Facility Name

Hospital of the University of Occupational and

City

Kitakyushu

State/Province

Fukuoka

ZIP/Postal Code

807-8556

Country

Japan

Facility Name

Gifu Univiesity Hospital

City

Gifu-shi

State/Province

Gifu

ZIP/Postal Code

501-1194

Country

Japan

Facility Name

Gunma University Hospital

City

Maebashi-shi

State/Province

Gunma

ZIP/Postal Code

371-8511

Country

Japan

Facility Name

National Hospital Organization Kure Medical Center

City

Kure

State/Province

Hiroshima

ZIP/Postal Code

737-0023

Country

Japan

Facility Name

Koube University Hospital

City

Kobe-shi

State/Province

Hyogo

ZIP/Postal Code

650-0017

Country

Japan

Facility Name

Hyogo College of Medicine

City

Nishinomiya-shi

State/Province

Hyogo

ZIP/Postal Code

663-8501

Country

Japan

Facility Name

Kanazawa University Hospital

City

Kanazawa

State/Province

Ishikawa

ZIP/Postal Code

920-8641

Country

Japan

Facility Name

Sendai Kousei Hospital

City

Sendai

State/Province

Miyagi

ZIP/Postal Code

980-0873

Country

Japan

Facility Name

Kurashiki Central Hospital

City

Kurashiki

State/Province

Okayama

ZIP/Postal Code

710-8602

Country

Japan

Facility Name

Kansai Medical University Hospital

City

Hirakata

State/Province

Osaka

ZIP/Postal Code

573-1191

Country

Japan

Facility Name

Kinki University Hospital Faculty of Medicine

City

Osaka-Sayama

State/Province

Osaka

ZIP/Postal Code

589-8511

Country

Japan

Facility Name

National Hospital Organization Kinki-Chuo

City

Sakai

State/Province

Osaka

ZIP/Postal Code

591-8555

Country

Japan

Facility Name

Tottori University Hospital

City

Yonago

State/Province

Tottori

ZIP/Postal Code

683-8504

Country

Japan

Facility Name

National Hospital Organization Yamaguchi

City

Ube

State/Province

Yamaguchi

ZIP/Postal Code

755-0241

Country

Japan

Facility Name

Chiba University Hospital

City

Chiba

ZIP/Postal Code

260-8677

Country

Japan

Facility Name

National Hospital Organization Kyushu Medical Center

City

Fukuoka

ZIP/Postal Code

810-8563

Country

Japan

Facility Name

Kyushu University Hospital

City

Fukuoka

ZIP/Postal Code

812-8582

Country

Japan

Facility Name

Hiroshima City Hiroshima Citizens Hospital

City

Hiroshima

ZIP/Postal Code

730-8518

Country

Japan

Facility Name

Hiroshima University Hospital

City

Hiroshima

ZIP/Postal Code

734-8551

Country

Japan

Facility Name

Osaka City General Hospital

City

Osaka

ZIP/Postal Code

534-0021

Country

Japan

Facility Name

Osaka International Cancer Institute

City

Osaka

ZIP/Postal Code

537-8511

Country

Japan

Facility Name

Juntendo University Hospital

City

Tokyo

ZIP/Postal Code

113-8431

Country

Japan

Facility Name

Tokyo Medical University Hospital

City

Tokyo

ZIP/Postal Code

160-0023

Country

Japan

Facility Name

Kanagawa Cancer Center

City

Yokohama City

ZIP/Postal Code

241-0815

Country

Japan

Facility Name

Chungbuk National University Hospital

City

Cheongju

State/Province

Chungcheongbuk Do

ZIP/Postal Code

362-711

Country

Korea, Republic of

Facility Name

Keimyung University Dongsan Medical Center

City

Daegu

State/Province

Dalseogu

ZIP/Postal Code

42601

Country

Korea, Republic of

Facility Name

Chung Ang University Hospital

City

Seoul

State/Province

Dongjak Gu

ZIP/Postal Code

156-755

Country

Korea, Republic of

Facility Name

Veterans Health Service Medical Center

City

Seoul

State/Province

Gangdong-gu

ZIP/Postal Code

134-791

Country

Korea, Republic of

Facility Name

The Catholic University of Korea Bucheon

City

Bucheon

State/Province

Gyeonggi Do

ZIP/Postal Code

420-717

Country

Korea, Republic of

Facility Name

Ajou University Hospital

City

Suwon

State/Province

Gyeonggi Do

ZIP/Postal Code

443-380

Country

Korea, Republic of

Facility Name

Uijeongbu ST Marys Hospital

City

Gyeonggi-do

ZIP/Postal Code

11765

Country

Korea, Republic of

Facility Name

Kangbuk Samsung Hospital

City

Seoul

ZIP/Postal Code

03181

Country

Korea, Republic of

Facility Name

The Catholic University of Korea,

City

Seoul

ZIP/Postal Code

137-701

Country

Korea, Republic of

Facility Name

Universitair medisch centrum Nijmegen st Radboud

City

Nijmegen

State/Province

Gelderland

ZIP/Postal Code

6525 GA

Country

Netherlands

Facility Name

Amphia ziekenhuis

City

Breda

State/Province

Noord Brabant

ZIP/Postal Code

4818 CK BREDA

Country

Netherlands

Facility Name

Tergooi locatie Hilversum

City

Hilversum

State/Province

Noord Holland

ZIP/Postal Code

1213XZ

Country

Netherlands

Facility Name

Isala

City

Zwolle

State/Province

Overijssel

ZIP/Postal Code

8025 AB

Country

Netherlands

Facility Name

Netherlands Cancer Institute

City

Amsterdam

ZIP/Postal Code

1066 CX

Country

Netherlands

Facility Name

Free University Hospital

City

Amsterdam

Country

Netherlands

Facility Name

UMC Groningen

City

Groningen

ZIP/Postal Code

9713 GZ

Country

Netherlands

Facility Name

Academical Hospital Maastricht

City

Maastricht

ZIP/Postal Code

622G HX

Country

Netherlands

Facility Name

Erasmus Medical Center (EMC)

City

Rotterdam

Country

Netherlands

Facility Name

Christchurch Hospital

City

Christchurch

Country

New Zealand

Facility Name

Klinika Onkologii i Radioterapii Uniwersyteckie

City

Gdansk

ZIP/Postal Code

80-214

Country

Poland

Facility Name

Specjalistyczny Szpital im

City

Szczecin

ZIP/Postal Code

70 891

Country

Poland

Facility Name

Samodzielny Publiczny Szpital Specjalistyczny

City

Zakopane

ZIP/Postal Code

34 500

Country

Poland

Facility Name

Conformal Med Terra HIFU

City

Bucharest

ZIP/Postal Code

031864

Country

Romania

Facility Name

Spitalul de Psihiatrie Dr. Constantin Gorgos

City

Bucharest

ZIP/Postal Code

30447

Country

Romania

Facility Name

Oncology Institute Bucharest

City

Bucharest

Country

Romania

Facility Name

Oncological Institute "Ion Chiricuta"

City

Cluj-Napoca

ZIP/Postal Code

3400

Country

Romania

Facility Name

OCH - Ovidius Clinical Hospital

City

Constanta

ZIP/Postal Code

905900

Country

Romania

Facility Name

Centrul de Oncologie Sf Nectarie

City

Craiova

ZIP/Postal Code

200347

Country

Romania

Facility Name

SC Oncolab SRL

City

Craiova

ZIP/Postal Code

200385

Country

Romania

Facility Name

Spital Lotus SRL

City

Ploiesti

ZIP/Postal Code

100011

Country

Romania

Facility Name

National University Hospital

City

Singapore

ZIP/Postal Code

119074

Country

Singapore

Facility Name

Hospital Germans Trias i Pujol

City

Badalona

State/Province

Barcelona

ZIP/Postal Code

08916

Country

Spain

Facility Name

Hospital Mutua de Terrassa

City

Terrassa

State/Province

Barcelona

ZIP/Postal Code

08221

Country

Spain

Facility Name

Hospital Insular de Gran Canaria

City

Las Palmas

State/Province

Gran Canaria

ZIP/Postal Code

35016

Country

Spain

Facility Name

Hospital General de Alicante

City

Alicante

ZIP/Postal Code

03010

Country

Spain

Facility Name

Hoapital Quiron Dexeus

City

Barcelona

ZIP/Postal Code

08028

Country

Spain

Facility Name

Hospital Vall d Hebron

City

Barcelona

ZIP/Postal Code

08035

Country

Spain

Facility Name

Hospital de la Santa Creu i Sant Pau

City

Barcelona

ZIP/Postal Code

08041

Country

Spain

Facility Name

Hospital Duran i Reynals

City

Barcelona

ZIP/Postal Code

08907

Country

Spain

Facility Name

Hospital Teresa Herrera

City

Coruna

ZIP/Postal Code

15006

Country

Spain

Facility Name

Complejo Asistencial Universitario de Leon

City

Leon

ZIP/Postal Code

24071

Country

Spain

Facility Name

Hospital Universitario la Princesa

City

Madrid

ZIP/Postal Code

28006

Country

Spain

Facility Name

Hospital Puerta de Hierro

City

Madrid

ZIP/Postal Code

28035

Country

Spain

Facility Name

Fundacion Jimenez Diaz

City

Madrid

ZIP/Postal Code

28040

Country

Spain

Facility Name

Hospital Clinico San Carlos

City

Madrid

ZIP/Postal Code

28040

Country

Spain

Facility Name

Hospital Son Llatzer

City

Palma de Mallorca

ZIP/Postal Code

07198

Country

Spain

Facility Name

Hospital Universitario de Salamanca

City

Salamanca

ZIP/Postal Code

37007

Country

Spain

Facility Name

Hospital General Universitario de Valencia

City

Valencia

ZIP/Postal Code

46014

Country

Spain

Facility Name

Far Eastern Memorial Hospital

City

New Taipei City;

State/Province

Taiwan;

ZIP/Postal Code

220

Country

Taiwan

Facility Name

Chang-Gung Memorial Hospital - Chiayi

City

Chiayi City

ZIP/Postal Code

613

Country

Taiwan

Facility Name

E-Da Hospital

City

Kaohsiung City

ZIP/Postal Code

82445

Country

Taiwan

Facility Name

Kaohsiung Medical University

City

Kaohsiung

ZIP/Postal Code

807

Country

Taiwan

Facility Name

Chang-Gung Memorial Hospital - Kaohsiung

City

Kaohsiung

ZIP/Postal Code

833

Country

Taiwan

Facility Name

Taipei Medical University - Shuang Ho Hospital

City

New Taipei City

ZIP/Postal Code

235

Country

Taiwan

Facility Name

China Medical University Hospital

City

Taichung

ZIP/Postal Code

404

Country

Taiwan

Facility Name

Mackay Memorial Hospital

City

Taipei

ZIP/Postal Code

104

Country

Taiwan

Facility Name

Veterans General Hospital - Taipei

City

Taipei

ZIP/Postal Code

112

Country

Taiwan

Facility Name

Tri-Service General Hospital

City

Taipei

ZIP/Postal Code

114

Country

Taiwan

Facility Name

Chang-Gung Memorial Hospital - Linkou

City

Taoyuan

ZIP/Postal Code

333

Country

Taiwan

Facility Name

Dnipropetrovsk City Clinical Hospital No.4

City

Dnipropetrovsk

ZIP/Postal Code

49102

Country

Ukraine

Facility Name

Regional Oncology Center

City

Sumy

ZIP/Postal Code

40004

Country

Ukraine

Facility Name

Vinnytsia Regional Clinical Oncology Dispensary

City

Vinnitsia

ZIP/Postal Code

21029

Country

Ukraine

12. IPD Sharing Statement

Plan to Share IPD

Learn more about this trial

Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC

We'll reach out to this number within 24 hrs

Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC

Non-Small Cell Lung Cancer

About this trial

Eligibility Criteria

Sites / Locations

Arms of the Study

Arm 1

Arm 2

Outcomes

Primary Outcome Measures

Secondary Outcome Measures

Full Information

1. Study Identification

2. Study Status

3. Sponsor/Collaborators

4. Oversight

5. Study Description

6. Conditions and Keywords

7. Study Design

8. Arms, Groups, and Interventions

10. Eligibility

12. IPD Sharing Statement

Learn more about this trial